Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease.
Adult
Endothelial Cells
/ pathology
Female
Gastrointestinal Hemorrhage
/ complications
Graft vs Host Disease
/ diagnosis
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Intestinal Diseases
/ diagnosis
Male
Middle Aged
Prospective Studies
Thrombosis
/ etiology
Thrombotic Microangiopathies
/ diagnosis
Transplantation, Homologous
/ adverse effects
Young Adult
Endoscopy
Graft-versus-host disease
Hematopoietic cell transplantation
Intestinal
Thrombotic microangiopathy
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
07
08
2019
accepted:
25
09
2019
revised:
23
09
2019
pubmed:
6
10
2019
medline:
14
4
2020
entrez:
6
10
2019
Statut:
ppublish
Résumé
Transplant-associated thrombotic microangiopathy (TA-TMA) is a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT) with multisystem involvement. Cases of TMA in the intestinal vasculature (intestinal TMA/iTMA) have been reported. We hypothesized that iTMA is a distinct entity from TA-TMA. To test this hypothesis, we prospectively recruited allo-HCT recipients with an indication for endoscopy. Among 20 patients, histological features of iTMA, including loss of glands, total denudation of mucosa, apoptosis and detachment of endothelial cells, mucosal hemorrhage, intraluminal fibrin and microthrombi were found in six. Only 2/6 were classified as GVHD/TA-TMA, while the other 4 as GVHD/no TA-TMA. Gastro-intestinal symptoms were similar between the patients with or without iTMA. With a median follow-up of 11.1 (2.1-67.5) months, 1-year overall survival was 22.2% for iTMA, 55% for GVHD and 60% for TA-TMA. On multivariate analysis, independent unfavorable predictors of OS were iTMA (p = 0.048), HLA mismatched donors (p = 0.008) and gastro-intestinal bleeding (p = 0.021). In conclusion, iTMA emerges as a novel distinct entity in patients with GVHD and/or TA-TMA. Distinct histological features may be useful in differential diagnosis of these severe HCT complications. The higher mortality rates of iTMA than TA-TMA highlight the need for further investigation of this condition.
Identifiants
pubmed: 31586304
doi: 10.1007/s12185-019-02750-7
pii: 10.1007/s12185-019-02750-7
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
529-532Subventions
Organisme : European Hematology Association
ID : Clinical Research Grant 2016
Références
Eur J Haematol. 2009 Sep;83(3):277
pubmed: 19467016
Bone Marrow Transplant. 2017 Oct;52(10):1355-1360
pubmed: 28287636
Hematol Oncol. 2017 Dec;35(4):932-934
pubmed: 27641429
Biol Blood Marrow Transplant. 2015 Nov;21(11):1994-2001
pubmed: 26150023
Blood Adv. 2018 Oct 23;2(20):2619-2628
pubmed: 30327370
Tohoku J Exp Med. 2012;227(1):31-7
pubmed: 22531159
Clin Transplant. 2018 Sep;32(9):e13371
pubmed: 30080283
Transplant Proc. 2010 Nov;42(9):3892-3
pubmed: 21094879
Bone Marrow Transplant. 2004 Jun;33(11):1143-50
pubmed: 15077133
Transplant Proc. 2014 Jun;46(5):1536-9
pubmed: 24935326
Bone Marrow Transplant. 2005 Sep;36(6):517-23
pubmed: 16025150
Bone Marrow Transplant. 2009 Jul;44(1):43-9
pubmed: 19139727
Int Surg. 2012 Jan-Mar;97(1):14-6
pubmed: 23101995
Haematologica. 2007 Jan;92(1):95-100
pubmed: 17229640